Common cold
Conditions
Interventions
Placebo food, one tablet/day, 20 consecutive weeks.
Food containing 4x9E10 b240, one tablet/day, 20 consecutive weeks
Food containing 4x10E10 b240, one tablet/day, 20 consecutive weeks
Sponsors
Otsuka Pharmaceutical Co., Ltd.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Of the elderly individuals who gave informed consent in writing, those satisfying the requirements listed in 1) received screening test. The individuals judged by the Investigator or Sub-investigator as appropriate for the study were enrolled as subjects. 1)Healthy males and females aged over 65 at the time of acquisition of informed consent in writing
Exclusion criteria
Exclusion criteria: 1)Smokers 2)Individuals practicing intensive exercise continuously 3)Individuals with laboratory parameters, blood pressure or heart rate markedly deviated from the normal range 4)Individuals with a history of gastrointestinal or immunological diseases, such as pneumonia, cancer, inflammatory bowel disease or rheumatism etc. 5)Individuals with bleeding or inflammation in the oral cavity 6)Individuals having received antibiotics during the period between 2 weeks before the screening test and the start of test food intake 7)Other individuals judged as inappropriate for the study by the physician in charge
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of common cold | — |
Secondary
| Measure | Time frame |
|---|---|
| 1)Salivary SIgA secretion 2)QOL | — |
Countries
Japan
Contacts
Public ContactMasamichi Toba
Otsuka Pharmaceutical Co., Ltd. Otsu Nutraceuticals research institute
Outcome results
None listed